Back to top
more

Beam Therapeutics (BEAM)

(Delayed Data from NSDQ)

$25.62 USD

25.62
1,750,612

-1.26 (-4.69%)

Updated Jul 15, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.

Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review

The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.

Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate

Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.

Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

TELA Bio, Inc. (TELA) Stock Jumps 6.6%: Will It Continue to Soar?

TELA Bio, Inc. (TELA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?

Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 8.18% and 89.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 16.67% and 483.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Pfizer (PFE) to Ride on COVID Jab & Pill in 2022: What Next?

Pfizer's (PFE) COVID-19 vaccine and its oral antiviral pill for COVID-19, Paxlovid are expected to generate a combined $54 billion in sales in 2022.

The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo

Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Research Deal With BEAM & Other Updates

Pfizer (PFE) inks research collaboration with Beam Therapeutics. Merck's (MRK) Keytruda improves survival in adjuvant lung cancer

Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs

Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 46.15% and -95.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Analysts Estimate Beam Therapeutics Inc. (BEAM) to Report a Decline in Earnings: What to Look Out for

Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

Indrajit Bandyopadhyay headshot

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.

Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease

Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.

Editas (EDIT) Down on Initial Data From Eye Disease Study

Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.

Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.